Two year interim analysis of thyroid abnormalities in a trial of alemtuzumab vs high-dose interferon-beta-1a, for treatment of relapsing-remitting multiple sclerosis
Two year interim analysis of thyroid abnormalities in a trial of alemtuzumab vs high-dose interferon-beta-1a, for treatment of relapsing-remitting multiple sclerosis. Multiple Sclerosis. 2006; 12(Supplement 1 (Late Breaking)):P799.